(Q37976876)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Role of modelling and simulation: a European regulatory perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Anja Henningsson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Monica Edholm

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Tomas Salmonson

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

69-76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22257148%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/11596650-000000000-00000

20 January 2020

exact match

0 references

cites work

Learning versus confirming in clinical drug development

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe' paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Expanding clinical applications of population pharmacodynamic modelling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Modelling during drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Simulation of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Clinical trial simulation in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Pharmacokinetic/pharmacodynamic modeling in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Role of modelling and simulation in Phase I drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Pharmacokinetic/pharmacodynamic studies in drug product development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Impact of population pharmacokinetic-pharmacodynamic analyses on the drug development process: experience at Parke-Davis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development: the capecitabine experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

How modeling and simulation have enhanced decision making in new drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Model-based drug development: the road to quantitative pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Pharmacometrics and the transition to model-based development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Paving the critical path: how can clinical pharmacology help achieve the vision?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Pharmacometrics for regulatory decision making: status and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Role of modeling and simulation in pediatric investigation plans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Proposals for model-based paediatric medicinal development within the current European Union regulatory framework

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

21 January 2018

Pharmacometrics 2020.

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

Randomized exposure-controlled trials; impact of randomization and analysis strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596650-000000000-00000

An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22257148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22257148

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22257148